newsfilter
← Latest News
Earnings Call Transcripts·

Twist Bioscience Corporation at Jefferies Global Healthcare Conference in London - TWIST BIOSCIENCE CORP

  • Financial Performance:

    • 2025 full-year revenue was $210 million; 2026 revenue grew 175% year-over-year to $590 million.
    • Achieved EBITDA break-even for the first time in the most recent quarter.
    • Total addressable market (TAM) expanded from $2 billion in 2021 to $7 billion currently, with a line of sight to $13 billion.
    • AI drug discovery revenue reached $21 million in 2025 and $59 million in 2026; guidance set for at least $100 million in 2027.
    • Company-wide revenue guidance for 2027 is $550 million to $560 million.
    • Academic and government markets remain a low-double-digit percentage of mix but showed over 20% growth in Q4.
  • Guidance and Future Outlook:

    • 2027 total revenue guidance of $550–$560 million implies low-20% organic growth.
    • AI drug discovery is expected to see triple-digit growth in 2027, with revenue potentially exceeding the $100 million guide if capacity constraints are resolved.
    • Management anticipates upside from MRD (Minimal Residual Disease) expansion, NGS adoption, and a potential rebound in academic/government funding, though these are not fully baked into the current guidance.
    • Long-term goal is to scale the platform to support $13 billion in total serviceable market opportunity.
  • Business Segments and Product Lines:

    • AI Drug Discovery: Customers follow a three-phase lifecycle (pilot, model building, production); revenue is shifting from lumpy pilot orders to predictable, recurring production revenue.
    • Cell-Free Synthesis: Recently launched a scaled cell-free offering for both single and multi-domain proteins, distinguishing Twist from competitors limited to single domains; this segment offers faster turnaround (weeks faster than cell-based) but lower material yield.
    • MRD (Minimal Residual Disease): Expected to be a major growth driver in 2027 and beyond; requires massive scale in probe synthesis (thousands of probes vs. standard 16), favoring Twist's silicon chip technology.
    • Pooled Discovery: Pursuing a strategy to shift market from arrayed discovery (1 sequence/tube) to pooled discovery to significantly reduce cost per data point while maintaining quality and speed.
    • Product Cadence: Continuous introduction of new DNA flavors to serve emerging applications in therapeutics and diagnostics.
  • Market and Competitive Landscape:

    • AI Drug Discovery: Market is broadening beyond "Magnificent 7" tech-bio companies to include major pharma (e.g., Eli Lilly) and those not yet fully converted to AI workflows.
    • Modality Evolution: Customers are moving from simple single-domain proteins to complex multi-domain and multi-specific antibodies, driving demand for higher data volumes.
    • Natera Dynamics: While Natera sets the gold standard in MRD testing, Twist positions itself as a critical upstream enabler, specifically for the high-sensitivity requirements of next-generation MRD assays.
    • Competitive Edge: Twist's unique silicon chip platform allows for 1 million oligos in a 96-well footprint, enabling lower costs, higher speed, and the ability to produce pooled DNA at scale.
  • Risks and Challenges:

    • Capacity Constraints: Current revenue visibility for AI discovery beyond $100 million is limited by manufacturing capacity rather than demand; scaling requires significant lead times for "riders" and automation.
    • Execution Risk: Scaling capacity 3x-4x is described as a logistical and organizational challenge ("cake eating") rather than a technical one, though software integration remains a rate-limiting step.
    • Market Recovery: Academic and government funding pressures could limit upside if the broader economy does not rebound as anticipated.
    • Technology Limits: Cell-free synthesis, while faster, currently yields less material and less comprehensive binding/developability data compared to cell-based gold standards.
  • Management Commentary and Tone:

    • Tone is highly confident, emphasizing "best in class" financial performance relative to peers and a successful shift to profitability (EBITDA break-even).
    • Management frames the company as a "technology platform" with a strong "foundry" model where volume drives down viable costs.
    • There is a clear narrative of moving from a lumpy, pilot-based revenue model in AI to a steady, recurring production model.
    • Management expresses strong conviction in the ability to take market share during tough economic cycles due to their value proposition of high quality, speed, and price.
  • Analyst Questions and Answers:

    • Q: What drives upside beyond the 2027 guide?
      • A: Upside lies in AI adoption across more pharma companies, migration up the modality value chain (complex antibodies), MRD growth, and a rebound in academic spending.
    • Q: Is the AI growth sustainable and predictable?
      • A: Yes; the 3-phase customer lifecycle allows for predictable modeling of demand a year in advance, allowing capacity to be built proactively.
    • Q: Is the CapEx increase risky?
      • A: Management states technical risk is minimal as CapEx involves replicating existing, proven instruments and automation ("copy-pasting"), with software integration being the primary hurdle.
    • Q: How does cell-free compare to cell-based?
      • A: Cell-free is significantly faster (weeks vs. months) and suitable for high-velocity discovery, though it provides less material and less rich data; Twist is the only supplier at scale offering both single and multi-domain cell-free.
  • Other Key Points:

    • CapEx Plan: $150 million allocated over the next two years ($75 million in 2026 and 2027), primarily to add manufacturing capacity for AI drug discovery (increasing "riders" from 10 to 16, expanding GeneLab 2 automation, and increasing characterization equipment).
    • Technology Differentiation: The core differentiator is writing DNA directly on a silicon chip, enabling 1 million oligos in a 96-well plate footprint, which drives massive throughput and low variable costs.
    • Strategic Focus: Shift towards "design, build, test, learn" workflows where Twist handles the wet lab "build and test" for AI-driven dry lab design.
    • Market Share: Twist is actively taking market share in difficult markets by offering superior value propositions during periods of customer cost sensitivity.
Company
TWIST BIOSCIENCE CORP
Keywords
TWIST BIOSCIENCE CORP